See more : American Potash Corp. (APCOF) Income Statement Analysis – Financial Results
Complete financial analysis of Geron Corporation (GERN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Geron Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Amita Holdings Co.,Ltd. (2195.T) Income Statement Analysis – Financial Results
- Alpha Growth plc (ALPGF) Income Statement Analysis – Financial Results
- Niagara Mohawk Power Corporation PFD 3.60% (NMK-PB) Income Statement Analysis – Financial Results
- Cummins Inc. (CMI) Income Statement Analysis – Financial Results
- First Miami Bancorp, Inc. (FMIA) Income Statement Analysis – Financial Results
Geron Corporation (GERN)
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 237.00K | 596.00K | 1.39M | 253.00K | 460.00K | 1.07M | 1.07M | 6.16M | 36.37M | 1.15M | 1.28M | 2.71M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 6.61M | 5.40M | 6.80M | 7.30M | 5.30M |
| Cost of Revenue | 123.74M | 868.00K | 783.00K | 50.05M | 51.27M | 12.72M | 8.44M | 14.70M | 9.57M | 8.90M | 9.13M | 25.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.65M | -3.70M | -1.70M | -1.60M | -1.20M |
| Gross Profit | -123.50M | -272.00K | 610.00K | -49.80M | -50.81M | -11.66M | -7.37M | -8.53M | 26.80M | -7.75M | -7.85M | -22.47M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 11.26M | 9.10M | 8.50M | 8.90M | 6.50M |
| Gross Profit Ratio | -52,110.97% | -45.64% | 43.79% | -19,683.40% | -11,046.09% | -1,093.53% | -692.21% | -138.48% | 73.68% | -671.99% | -611.93% | -829.42% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 170.40% | 168.52% | 125.00% | 121.92% | 122.64% |
| Research & Development | 125.05M | 95.52M | 85.73M | 51.49M | 52.07M | 13.43M | 11.03M | 18.05M | 17.83M | 20.71M | 23.16M | 51.37M | 69.32M | 61.69M | 57.62M | 53.66M | 54.62M | 41.23M | 35.08M | 30.08M | 25.55M | 31.57M | 29.02M | 23.55M | 20.60M | 15.60M | 15.10M | 14.30M |
| General & Administrative | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Other Expenses | 0.00 | 1.00M | 1.10M | 168.00K | -69.00K | -154.00K | 0.00 | 0.00 | 1.31M | 0.00 | 0.00 | 5.45M | 5.45M | 35.00M | 57.62M | 0.00 | 54.62M | 0.00 | -5.87M | 45.15M | 0.00 | 0.00 | 0.00 | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| Operating Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 37.47M | 29.90M | 21.10M | 19.80M | 18.70M |
| Cost & Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 32.82M | 26.20M | 19.40M | 18.20M | 17.50M |
| Interest Income | 18.15M | 2.53M | 527.00K | 1.83M | 4.22M | 3.29M | 1.42M | 1.19M | 677.00K | 373.00K | 951.00K | 3.10M | 1.02M | 2.05M | 1.37M | 5.54M | 10.79M | 8.70M | 4.66M | 1.55M | 1.81M | 2.55M | 5.86M | 5.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.31M | 6.88M | 3.74M | 760.00K | 0.00 | 0.00 | 77.00K | 83.00K | 88.00K | 82.00K | 56.00K | 233.00K | 237.00K | 98.00K | 143.00K | 93.00K | 102.00K | 130.00K | 464.00K | 672.00K | 736.00K | 757.00K | 1.00M | 12.28M | 0.00 | 900.00K | 0.00 | 400.00K |
| Depreciation & Amortization | 1.03M | 868.00K | 783.00K | 935.00K | 776.00K | 59.00K | 76.00K | 81.00K | 56.00K | 47.00K | 320.00K | 830.00K | 1.58M | 1.61M | 1.75M | 2.42M | 1.93M | 1.59M | 3.74M | 3.91M | 4.12M | 4.59M | 4.37M | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| EBITDA | -174.78M | -134.15M | -111.59M | -73.92M | -67.77M | -26.96M | -29.18M | -30.57M | 803.00K | -35.62M | -38.06M | -67.82M | -95.04M | -109.67M | -68.29M | -59.91M | -62.84M | -47.36M | -35.85M | -32.23M | -26.06M | -31.11M | -30.65M | -21.56M | -17.10M | -10.90M | -9.30M | -11.00M |
| EBITDA Ratio | -73,747.68% | -22,654.19% | -8,010.70% | -29,611.46% | -15,761.96% | -3,051.88% | -2,613.99% | -477.99% | 3.92% | -3,117.00% | -2,823.46% | -2,434.81% | -3,388.72% | -1,160.74% | -4,078.27% | -2,320.37% | -1,001.86% | -1,623.19% | -13,736.21% | 1,226.97% | -2,153.24% | -2,492.79% | -517.65% | -326.21% | 116.67% | -200.00% | -152.05% | -241.51% |
| Operating Income | -193.94M | -138.55M | -114.00M | -76.91M | -72.51M | -31.07M | -29.26M | -30.65M | -559.00K | -36.31M | -38.96M | -71.76M | -96.12M | -111.17M | -70.23M | -67.04M | -62.84M | -47.36M | -37.71M | -81.29M | -30.18M | -35.70M | -35.02M | -26.21M | -20.80M | -12.60M | -10.90M | -12.20M |
| Operating Income Ratio | -81,832.91% | -23,246.64% | -8,183.70% | -30,400.40% | -15,761.96% | -2,914.92% | -2,746.95% | -497.34% | -1.54% | -3,149.35% | -3,036.48% | -2,648.87% | -3,942.41% | -3,120.04% | -4,069.18% | -2,391.87% | -824.44% | -1,445.22% | -13,003.45% | -7,719.37% | -2,570.70% | -2,860.58% | -967.38% | -396.61% | -385.19% | -185.29% | -149.32% | -230.19% |
| Total Other Income/Expenses | 9.82M | -3.35M | -2.11M | 1.30M | 3.96M | 4.06M | 1.34M | 1.11M | 605.00K | 642.00K | 579.00K | 2.88M | -737.00K | -210.00K | 50.00K | 5.02M | 26.14M | 16.00M | 4.18M | 880.00K | 297.00K | 0.00 | -11.91M | 0.00 | -23.40M | 2.70M | 1.80M | 1.80M |
| Income Before Tax | -184.13M | -141.90M | -116.11M | -75.62M | -68.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | 0.00 | -46.93M | 0.00 | -44.20M | -9.90M | -9.10M | -10.40M |
| Income Before Tax Ratio | -77,690.72% | -23,808.89% | -8,335.39% | -29,888.14% | -14,901.74% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | 0.00% | -1,296.38% | 0.00% | -818.52% | -145.59% | -124.66% | -196.23% |
| Income Tax Expense | 0.00 | -868.00K | 4.84M | -7.00K | -5.00M | 4.06M | 1.34M | 1.11M | 32.00K | 35.00K | 56.00K | -597.00K | 5.68M | 31.25M | -3.14M | -5.87M | -26.14M | -16.00M | -4.19M | 44.27M | -297.00K | -1.79M | 7.05M | 19.62M | 25.60M | -1.80M | -1.30M | -1.50M |
| Net Income | -184.13M | -141.03M | -120.95M | -75.61M | -63.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | -33.91M | -42.07M | -45.83M | -46.40M | -10.80M | -9.60M | -10.70M |
| Net Income Ratio | -77,690.72% | -23,663.26% | -8,682.84% | -29,885.38% | -13,815.43% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | -2,716.99% | -1,162.24% | -693.49% | -859.26% | -158.82% | -131.51% | -201.89% |
| EPS | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -2.08 |
| EPS Diluted | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -1.38 |
| Weighted Avg Shares Out | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 158.04M | 153.54M | 127.93M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 5.15M |
| Weighted Avg Shares Out (Dil) | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 162.66M | 153.54M | 128.38M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 7.74M |
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron common stock as inducements to newly hired employees in connection...
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will...
Geron: Derisked And Highly Attractive After Approval
Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise in treating MDS and MF, with significant clinical trial results and manageable adverse...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron common stock as inducements to newly hired employees in connection...
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024....
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN...
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will...
3 Under-$10 Biotech Stocks That Could Make You Rich
Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout.
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
Source: https://incomestatements.info
Category: Stock Reports